

PROSTATE CANCER

A Major Issue for Public Health


PROSTATE CANCER IS THE MOST COMMON CANCER AMONG MEN, with more than 1.1 million new cases diagnosed every year worldwide, before lung cancer and colorectal cancer.

#3 Prostate cancer is the **THIRD** leading cause of cancer-related deaths in American men


It is estimated that **161,360** American men will be diagnosed with prostate cancer



1 IN 9
chance of eventually being diagnosed



1 IN 39
chance of dying from it



BIOPSIES ARE CRITICAL

and the only diagnostic test that confirms the presence of prostate cancer and evaluates prognosis.

99% OF BIOPSIES PERFORMED WORLDWIDE ARE "BLIND" resulting in low positive detection rates (20-30%).

A urologist can decide between fusion-targeted therapy with local anesthesia or a blind biopsy without general anesthesia.



BLIND BIOPSY is the removal of 12 to 40 spread samples.

- More samples to maximize the chances of finding an infected site
- Not as clear visualization of potential cancer on the ultrasound scanner
- Difficult to take an even spread of organ samples
- 30% MRI/US Fusion Cancer Detection Rate



FUSION-TARGETED BIOPSY is the removal of 3 to 18 samples.

- Locate suspect areas on the ultrasound image in realtime
- Guide biopsy needle directly into the suspect areas on the MRI
- Precision of a few millimeters
- 60% MRI/US Fusion Cancer Detection Rate

PROSTATE CANCER TUMOR IMAGING CHALLENGES



CHALLENGE 1

To localize and register patient's prostate and cancer lesions on a personalized 3D cartography



CHALLENGE 2

To give the urologist the means to pinpoint with exact precision



CHALLENGE 3

To validate a targeted treatment technique